A protective role for matrix metalloproteinase-3 in squamous cell carcinoma

Cancer Research

Volumn 64, Issue 19, 2004, Pages 6965-6972

  McCawley, Lisa J ^a   Crawford, Howard C ^a   King Jr , Lloyd E ^a   Mudgett, John ^b   Matrisian, Lynn M ^a,c  

^a VANDERBILT UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; METHYLNITRONITROSOGUANIDINE; PHORBOL 13 ACETATE 12 MYRISTATE; STROMELYSIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CELL INFILTRATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GROWTH RATE; LEUKOCYTE; LUNG METASTASIS; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; WILD TYPE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOCHEMISTRY; LEUKOCYTES; MALE; MATRIX METALLOPROTEINASE 3; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS;

EID: 4944235417     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0910     Document Type: Article

References (46)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
3. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
4. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40.
5. Egeblad M, Werb Z. New functions for the matrix metailoproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
6. Nagase H. Stromelysins 1 and 2. In: Parks WC and Mecham RP, editors. Matrix Metalloproteinases. San Diego: Academic Press; 1998. p. 43-84.
7. Abramson SR, Conner GE, Nagase H, Neuhaus I, Woessner JF, Jr. Characterization of rat uterine matrilysin and its cDNA Relationship to human pump-1 and activation of procollagenases. J Biol Chem 1995;270:16016-22.
8. Kerkela E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003;12:109-25.
9. Shima I, Sasaguri Y, Kusukawa J, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma: a clinicopathologic study. Cancer 1992;70:2747-53.
10. Kusukawa J, Sasaguri Y, Morimatsu M, Kameyama T. Expression of matrix metalloproteinase-3 in stage I and II squamous cell carcinoma of the oral cavity. J Oral Maxillofac Surg 1995;53:530-4.
11. Airola K, Johansson N, Kariniemi AL, Kahari VM, Saarialho-Kere UK. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Investig Dermatol 1997;109:225-31.
12. Kerkela E, Ala-aho R, Lohi J, Grenman R, Kahari V, Saarialho-Kere U. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer 2001;84:659-69.
13. Woessner J F, Nagase H. Matrix Metalloproteinases and TIMPs, 1st ed. New York: Oxford University Press, Inc.; 2000.
14. Sternlicht MD, Lochter A, Sympson CJ, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46.
15. Mudgett JS, Hutchinson NI, Chartrain NA, et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998;41:110-21.
16. Bullard KM, Lund L, Mudgett JS, et al. Impaired wound contraction in stromelysin-1-deficient mice. Ann Surg 1999;230:260-5.
17. Alexander CM, Selvarajan S, Mudgett J, Werb Z. Stromelysin-1 regulates adipogenesis during mammary gland involution. J Cell Biol 2001;152:693-703.
18. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001;21:1440-5.
19. van Meurs J, van Lent P, Holthuysen A, et al. Active matrix metalloproteinases are present in cartilage during immune complex-mediated arthritis: a pivotal role for stromelysin-1 in cartilage destruction. J Immunol 1999;163:5633-9.
20. Warner RL, Beltran L, Younkin EM, et al. Role of stromelysin I and gelatinase B in experimental acute lung injury. Am J Respir Cell Mol Biol 2001;24:537-44.
21. Wright JH, McDonnell S, Portella G, Bowden GT, Balmain A, Matrisian LM. A switch from stromal to tumor cell expression of stromelysin-1 mRNA associated with the conversion of squamous to spindle carcinomas during mouse skin tumor progression. Mol Carcinog 1994;10:207-15.
22. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998;58:5206-15.
23. Haro H, Crawford HC, Fingleton B, et al. Matrix metalloproteinase-3- dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J Clin Investig 2000;105:133-41.
24. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol 1997;6:199-213.
25. Madlener M, Parks WC, Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 1998;242:201-10.
26. Witty JP, Lempka T, Coffey RJ, Jr., Matrisian LM. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res 1995;55:1401-6.
27. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-ā in homeostasis and cancer. Nat Rev Cancer 2003;3:807-20.
28. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-β 1 release. Biochem J 1997;322:809-14.
29. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76.
30. Maeda S, Dean DD, Gomez R, Schwartz Z, Boyan BD. The first stage of transforming growth factor β1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int 2002;70:54-65.
31. Maeda S, Dean DD, Gay I, Schwartz Z, Boyan BD. Activation of latent transforming growth factor β1 by stromelysin 1 in extracts of growth plate chondrocyte-derived matrix vesicles. J Bone Miner Res 2001;16:1281-90.
32. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
33. Coussens LM, Werb Z. Inflammatory cells and cancer. Think different! J Exp Med 2001;193:F23-26.
34. Di Carlo E, Iezzi M, Pannellini T, et al. Neutrophils in anti-cancer immunological strategies: old players in new games. J Hematother Stem Cell Res 2001;10:739-48.
35. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
36. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252-7.
37. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001;276:28261-7.
38. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994;370:555-7.
39. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J Immunol 1998;161:3340-6.
40. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002;100:1160-7.
41. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001;276:43503-8.
42. Preece G, Murphy G, Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem 1996;271:11634-40.
43. Black RA. Tumor necrosis factor-α converting enzyme. Int J Biochem Cell Biol 2002;34:1-5.
44. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 1999;59:4516-8.
45. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
46. Rudolph-Owen LA, Hulboy DL, Wilson CL, Mudgett J, Matrisian LM. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 1997;138:4902-11.